Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 391

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part II, Item 6
Chunk 391
---
Table of Contents

ITEM 6.     EXHIBITS

EXHIBIT INDEX

Incorporated by ReferenceExhibitNumberDescriptionFormFile No.NumberFiling Date10.1#Notice of Partial Termination from Genzyme Corporation to the Registrant, dated February 24, 2025———Filed herewith10.2#Notice of Partial Termination from Takeda Pharmaceutical Company Limited to the Registrant, dated February 25, 2025———Filed herewith10.3Amended Outside Director Compensation Policy———Filed herewith31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith32.1*Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.———Furnished herewith32.2*Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.———Furnished herewith101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Incline XBRL document———Furnished herewith101.SCHInline XBRL Taxonomy Extension Schema Document.———Furnished herewith101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.———Furnished herewith101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.———Furnished herewith101.LABInline XBRL Taxonomy Extension Label Linkbase Document.———Furnished herewith101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.———Furnished herewith104The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2025, formatted in Inline XBRL (contained in Exhibit 101)———Furnished herewith

*The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Denali Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly